Q
QuantAbundance

Notícias

Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.

31,229 signal articles · 0 in last 24h · 160,153 total before filter · latest 6d ago
0last 24h
68last 7d
16● bullish (7d)
8● bearish (7d)
214publishers
AllMacro13Earnings25M&A4RegulatoryProductAnalyst1
✕ clear all filtersSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Experian H2 Earnings Call Highlights
MarketBeat140d agoneutral
Experian H2 Earnings Call Highlights

Experian (LON:EXPN) reported what Chief Executive Officer Brian Cassin called a “record year” for the year ended March 31, 2026, with organic revenue growth at the top end of expectations, margin expansion ahead of guidance and a new GBP 1 billion share buyback program. Cassin said the company deli

Nvidia earnings: TSM's results may give 'a clue' on what to expect
Yahoo Finance Video140d agoneutralVIDEO
Nvidia earnings: TSM's results may give 'a clue' on what to expect

Nvidia (NVDA) is rounding out the earnings season for the Magnificent Seven this week as the chipmaker prepares to release first quarter results this Wednesday, May 20. Bokeh Capital Partners founder and CIO Kimberly Forrest highlights what she expects to see from Nvidia's results, mentioning how Taiwan Semiconductor Manufacturing Company's (TSM) own results may hint at what's to come.

A Look At Vishay Precision Group’s Valuation After Strong Q1 Results And Upbeat Revenue Guidance
Simply Wall St.140d agobullish
A Look At Vishay Precision Group’s Valuation After Strong Q1 Results And Upbeat Revenue Guidance

Vishay Precision Group (VPG) shares are in focus after the company paired first quarter results with second quarter revenue guidance of US$85 million to US$90 million, alongside new commentary on the stock's recent momentum. See our latest analysis for Vishay Precision Group. The share price has pulled back 6.9% over the last day to US$97.95. This follows a sharp rise, with a 30 day share price return of 84.05% and a 1 year total shareholder return of 271.73%, reflecting strong recent...

Nvidia Earnings Can Affirm Chip Stock Rally or Spur Market Chaos
Bloomberg140d agobullish
Nvidia Earnings Can Affirm Chip Stock Rally or Spur Market Chaos

(Bloomberg) -- For much of the year, chip stocks have been powering the market higher. Now, Nvidia Corp.’s earnings have a chance to confirm that the rally has more room to run — or add another brick to investors’ wall of worry.Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensBilliona

5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call
StockStory140d agoneutral
5 Revealing Analyst Questions From Hims & Hers Health’s Q1 Earnings Call

Hims & Hers Health’s first quarter was marked by a significant strategic pivot in its weight loss business, which management described as a move to prioritize branded medications over compounded products. CEO Andrew Dudum highlighted that this shift resulted in near-term financial pressures, including restructuring charges and margin compression, as the company adapted to evolving consumer demand and regulatory developments. The company also experienced increased investment in technology and ope

Novanta’s Q1 Earnings Call: Our Top 5 Analyst Questions
StockStory140d agoneutral
Novanta’s Q1 Earnings Call: Our Top 5 Analyst Questions

Novanta’s first quarter saw a strong positive market reaction, reflecting confidence in management’s execution and commercial momentum. The company credited broad-based demand and robust bookings, particularly in the Robotics & Automation and Advanced Surgery businesses, as central to its performance. CEO Matthijs Glastra highlighted that every segment achieved double-digit bookings growth, with new product revenue rising sharply. Management specifically pointed to ongoing strength in medical co

5 Revealing Analyst Questions From Plug Power’s Q1 Earnings Call
StockStory140d agoneutral
5 Revealing Analyst Questions From Plug Power’s Q1 Earnings Call

Plug Power delivered first quarter results that exceeded Wall Street’s revenue expectations, prompting a positive market reaction. Management credited robust performance in its material handling, electrolyzer, and hydrogen fuel businesses, as well as significant progress on margins due to cost improvements. CEO Jose Luis Crespo highlighted that the renewed investment tax credit and greater operational efficiency were key contributors to the growth, with the company noting improved customer engag

Restaurant Brands (QSR) Beats Earnings Expectations as Burger King Stabilizes
Insider Monkey140d agobullish
Restaurant Brands (QSR) Beats Earnings Expectations as Burger King Stabilizes

Seth Klarman ranks among the richest hedge fund managers in the world. Accounting for a 10.44% share of the billionaire’s portfolio, Restaurant Brands International Inc. (NYSE:QSR) ranks as Seth Klarman’s top stock pick. Scotiabank increased its price target for Restaurant Brands International Inc. (NYSE:QSR) to $83 from $81 on May 7, retaining a Sector Perform […]

Mizuho Cuts Target on Moody’s (MCO) After Earnings Beat
Insider Monkey140d agoneutral
Mizuho Cuts Target on Moody’s (MCO) After Earnings Beat

Chris Hohn ranks among the list of the richest hedge fund managers in the world. While Genie Energy Ltd. (NYSE:GNE) remains the billionaire’s largest position, Moody’s Corporation (NYSE:MCO) ranks 4th on the list of Chris Hohn’s top holdings with a 12.67% portfolio share. On April 27, Mizuho cut its price target on Moody’s Corporation (NYSE:MCO) to […]

Nvidia Earnings Likely to Shine Even as Stock Underperforms
Barrons.com140d agobearish
Nvidia Earnings Likely to Shine Even as Stock Underperforms

Artificial-intelligence leader Nvidia has a big task when it reports first-quarter earnings later today: convince investors that the AI investment boom still has legs and that Nvidia won’t lose its pole position. Wall Street analysts expect the company to report earnings per share of $1.75, up from 81 cents a year ago. Nvidia remains the biggest winner of the AI age.

Credo Technology (CRDO) Soars 8% as Investors Gear Up for Earnings
Insider Monkey140d agobullish
Credo Technology (CRDO) Soars 8% as Investors Gear Up for Earnings

Credo Technology Group Holding Ltd. (NASDAQ:CRDO) is one of the 10 Stocks With Powerful Gains. Credo Technology snapped a five-day losing streak on Tuesday, surging 8.14 percent to close at $168.99 apiece, as investors resorted to bargain-hunting while repositioning portfolios ahead of the results of its earnings performance for the fourth quarter and fiscal year […]

Ridgepost Capital (RPC): Buy, Sell, or Hold Post Q1 Earnings?
StockStory140d agoneutral
Ridgepost Capital (RPC): Buy, Sell, or Hold Post Q1 Earnings?

Over the last six months, Ridgepost Capital’s shares have sunk to $8.31, producing a disappointing 11.1% loss - a stark contrast to the S&P 500’s 13.3% gain. This was partly driven by its softer quarterly results and might have investors contemplating their next move.

Assessing Procter & Gamble (PG) Valuation After Q3 Earnings Beat And Ongoing Productivity Plan
Simply Wall St.140d agobullish
Assessing Procter & Gamble (PG) Valuation After Q3 Earnings Beat And Ongoing Productivity Plan

Procter & Gamble (PG) is back in focus after reporting Q3 FY2026 results that exceeded earnings expectations, paired with broad-based sales growth and reaffirmed guidance that kept its full-year outlook intact. See our latest analysis for Procter & Gamble. Despite Q3 earnings coming in ahead of expectations, Procter & Gamble’s recent share price momentum has softened, with the stock down almost 10% on a 90‑day share price return basis and the 1‑year total shareholder return declining about...

Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
StockStory140d agoneutral
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions

Halozyme Therapeutics’ first quarter results for 2026 were met with a positive market response, underpinned by substantial royalty revenue growth and the expanding adoption of subcutaneous drug delivery through its ENHANZE technology. CEO Helen Torley credited the quarter’s momentum to broader use of key partner products such as DARZALEX, VYVGART Hytrulo, and PHESGO, with royalty streams up 43% year-over-year. The company also benefited from ramping contributions from recently launched therapies